Neurocrine Bio. (NBIX) PT Lowered to $187 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $142.02 -0.89%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 15
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 15
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $187.00 (from $198.00) while maintaining a Outperform rating.
You May Also Be Interested In
- UCB SA (UCB:BB) (UCBJY) PT Raised to EUR340 at TD Cowen
- RingCentral (RNG) PT Raised to $105 at FBN Securities
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
